keyword
MENU ▼
Read by QxMD icon Read
search

capecitabine

keyword
https://www.readbyqxmd.com/read/28917648/challenges-of-conducting-a-prospective-clinical-trial-for-older-patients-lessons-learned-from-ncctg-n0949-alliance
#1
Nadine J McCleary, Joleen Hubbard, Michelle R Mahoney, Jeffrey A Meyerhardt, Daniel Sargent, Alan Venook, Axel Grothey
OBJECTIVES: While the risk of developing colorectal cancer increases with age, there are limited prospective data regarding best treatment in the older adult population. We launched a phase III trial to evaluate difference in treatment outcome for older adults (aged ≥70years) with advanced colorectal cancer. Here we review the challenges faced and reasons for poor accrual to N0949. MATERIALS AND METHODS: We describe the conceptualization, development and limited results of N0949, a randomized phase III study of fluoropyrimidine/bevacizumab with or without oxaliplatin (mFOLFOX7 or XELOX) as first line chemotherapy for metastatic colorectal cancer...
September 13, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28913549/multicenter-phase-ii-study-of-capecitabine-plus-cisplatin-as-first-line-therapy-for-human-epidermal-growth-factor-receptor-2-negative-advanced-gastric-cancer-yokohama-clinical-oncology-group-study-ycog1107
#2
Kei Sato, Chikara Kunisaki, Takashi Kosaka, Ryo Takagawa, Masazumi Takahashi, Yusuke Izumisawa, Hiroshi Miyamoto, Sho Sato, Yusaku Tanaka, Naotaka Yamaguchi, Jun Kimura, Hidetaka A Ono, Hirochika Makino, Hirotoshi Akiyama, Itaru Endo
PURPOSE: S-1 plus cisplatin therapy is the recommended standard first-line regimen for human epidermal growth factor receptor 2 (HER-2)-negative advanced unresectable or recurrent gastric cancer (AGC) in the Japanese Gastric Cancer Treatment Guidelines. By contrast, capecitabine plus cisplatin (XP) therapy has been second-line therapy for these patients. This prospective study aimed to evaluate the efficacy and safety of XP as a first-line regimen for HER2-negative patients with AGC. METHODS: In this multicenter, open-label, phase II study, patients received cisplatin (80 mg/m(2) i...
September 14, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28911067/maintenance-treatment-with-capecitabine-and-bevacizumab-versus-observation-in-metastatic-colorectal-cancer-updated-results-and-molecular-subgroup-analyses-of-the-phase-3-cairo3-study
#3
K K H Goey, S G Elias, H van Tinteren, M M Laclé, S M Willems, G J A Offerhaus, W W J de Leng, E Strengman, A J Ten Tije, G-J M Creemers, A van der Velden, F E de Jongh, F L G Erdkamp, B C Tanis, C J A Punt, M Koopman
Background: The phase 3 CAIRO3 study showed that capecitabine plus bevacizumab (CAP-B) maintenance treatment after six cycles capecitabine, oxaliplatin, and bevacizumab (CAPOX-B) in metastatic colorectal cancer (mCRC) patients is effective, without compromising quality of life. In this post hoc analysis with updated follow-up and data regarding sidedness, we defined subgroups according to RAS/BRAF mutation status and mismatch repair (MMR) status, and investigated their influence on treatment efficacy...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28906589/neoadjuvant-therapy-of-bevacizumab-in-combination-with-oxaliplatin-and-capecitabine-xelox-for-patients-with-metastatic-colorectal-cancer-with-unresectable-liver-metastases-a-phase-ii-open-label-single-arm-noncomparative-trial
#4
Hong-Hwa Chen, Jen-Kou Lin, Joe-Bin Chen, Chieh-Han Chuang, Mei-Ching Liu, Jen-Yi Wang, Chung-Rong Changchien
AIM: This phase II, open-label study evaluated the efficacy and safety of neoadjuvant therapy with bevacizumab plus XELOX (capecitabine and oxaliplatin) for untreated metastatic colorectal cancer with unresectable liver metastases and assessed conversion of unresectable to resectable metastases after neoadjuvant treatment. METHODS: Patients received bevacizumab 5 mg/kg and oxaliplatin 85 mg/m(2) on day 1, and capecitabine 1000 mg/m(2) twice daily on days 1-5 followed by 2 days of rest in a 14-day cycle for 12 cycles; bevacizumab was excluded in cycles 6 and 7...
September 14, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28900996/-clinicopathologic-characteristics-and-prognosis-of-gastric-hepatoid-adenocarcinoma
#5
Rongfei Zhao, Xinxin Wang, Xin Lan, Mingsen Li
OBJECTIVE: To investigate the clinicopathological characteristics, diagnosis, treatment and prognosis of gastric hepatoid adenocarcinoma(HAS). METHODS: Retrospective analysis of clinicopathological data of 24 cases with gastric HAS diagnosed by surgery and pathology in Chinese PLA General Hospital from January 2013 to May 2016 were carried out. All the patients underwent preoperative serum alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), endoscopy and imaging examination (CT or B-mode ultrasonography), and those with elevated AFP were excluded from liver cancer, cirrhosis, endodermal sinus tumor and other diseases...
September 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28900245/the-role-of-metronomic-capecitabine-for-treatment-of-recurrent-hepatocellular-carcinoma-after-liver-transplantation
#6
Matteo Ravaioli, Alessandro Cucchetti, Antonio Daniele Pinna, Vanessa De Pace, Flavia Neri, Maria Aurelia Barbera, Lorenzo Maroni, Giorgio Frega, Andrea Palloni, Stefania De Lorenzo, Maria Cristina Ripoli, Maria Abbondanza Pantaleo, Matteo Cescon, Massimo Del Gaudio, Giovanni Brandi
The management of recurrent hepatocellular carcinoma untreatable with surgical options is based on systemic therapy with sorafenib. Due to the high rates of adverse events connected to the therapy with sorafenib, metronomic capecitabine seems a promising strategy for these patients. We analyzed the data of 38 patients with hepatocellular carcinoma recurrent after liver transplantation performed at our center. We compared the outcome of 17 patients receiving metronomic capecitabine versus 20 patients experiencing best supportive care and versus the data of the literature about treatment with sorafenib...
September 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28894576/first-line-chemotherapy-with-capecitabine-oxaliplatin-for-advanced-gastric-cancer-a-phase-i-study
#7
Hironaga Satake, Hisateru Yasui, Takeshi Kotake, Yoshihiro Okita, Yukimasa Hatachi, Masahito Kotaka, Takeshi Kato, Akihito Tsuji
Combination chemotherapy with capecitabine and oxaliplatin for gastric cancer (G-XELOX) is considered as a potentially promising regimen. However, the use of the G-XELOX regimen in Japanese patients has not been investigated to date, and recommended doses of G-XELOX for Japanese patients with metastatic gastric cancer have not been established. The aim of the present study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) for systemic chemotherapy with G-XELOX for metastatic gastric cancer...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28890824/gemcitabine-and-capecitabine-for-advanced-biliary-cancer
#8
Emmanuel Gabriel, Shipra Gandhi, Kristopher Attwood, Boris Kuvshinoff, Steven Hochwald, Renuka Iyer
BACKGROUND: Gemcitabine with capecitabine (gem-cap) is an established regimen for advanced biliary cancer (ABC) supported by our previously reported phase II trial. Here, we provide our updated experience. METHODS: Single institution, retrospective study from 2005 to 2015 of ABC treated with gem-cap. RESULTS: A total of 372 patients with ABC were identified, of whom 227 (61.0%) were treated with chemotherapy. 153 patients (67.4%) received gem-cap, of which 129 (56...
August 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28881354/preoperative-capecitabine-oxaliplatin-and-irinotecan-in-resectable-gastric-or-gastroesophageal-junction-cancer-pathological-response-as-primary-endpoint-and-fdg-pet-predictions
#9
Rosa Berenato, Federica Morano, Filippo Pietrantonio, Christian Cotsoglou, Marta Caporale, Gabriele Infante, Alessandro Pellegrinelli, Alessandra Alessi, Carlo Battiston, Jorgelina Coppa, Barbara Padovano, Alessia Mennitto, Monica Niger, Giovanni Fucà, Silvia Lazzati, Giorgio Greco, Gabriele Delconte, Filippo de Braud, Vincenzo Mazzaferro, Maria Di Bartolomeo
OBJECTIVES: This phase II trial was aimed at assessing the safety and activity of capecitabine, oxaliplatin, and irinotecan (COI regimen) as a preoperative treatment for resectable gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. METHODS: Patients affected by T3-T4/N0-N+/M0 GC/GEJ cancer were treated with the COI regimen for 4 cycles followed by restaging and gastroresection with D2 lymphadenectomy. Four postoperative cycles were scheduled. The primary endpoint was pathological response rate according to Becker et al...
September 8, 2017: Oncology
https://www.readbyqxmd.com/read/28874896/phase-i-ii-trial-of-dose-reduced-capecitabine-in-elderly-patients-with-advanced-colorectal-cancer
#10
M D Vincent, D Breadner, M C Cripps, D J Jonker, P Klimo, J J Biagi, W Lam, A O'Connell, F Whiston, L Stitt, S A Welch
BACKGROUND: Combination chemotherapy is associated with improved outcomes in trials of selected fit patients with advanced colorectal cancer (acrc). For older or less-fit patients, combination chemotherapy is associated with greater toxicity and less benefit. Capecitabine monotherapy is a reasonable option for those patients, but the optimal dose remains controversial. METHODS: A multicentre phase i/ii trial of reduced-dose capecitabine (2000 mg/m(2), days 1-14 every 21 days) was conducted in 221 patients representing one or more of the following subsets: age greater than 65 years (n = 167), Eastern Cooperative Oncology Group (ecog) performance status of 1 or greater (n = 139), elevated lactate dehydrogenase (ldh) (n = 105), or prior pelvic radiation (n = 54)...
August 2017: Current Oncology
https://www.readbyqxmd.com/read/28874597/risk-of-febrile-neutropenia-associated-with-select-myelosuppressive-chemotherapy-regimens-in-a-large-community-based-oncology-practice
#11
Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H Page, Chun Chao
Background: NCCN has classified commonly used chemotherapy regimens into high (>20%), intermediate (10%-20%), or low (<10%) febrile neutropenia (FN) risk categories based primarily on clinical trial evidence. Many chemotherapy regimens, however, remain unclassified by NCCN or lack FN incidence data in real-world clinical practice. Patients and Methods: We evaluated incidence proportions of FN and grade 4 and 3/4 neutropenia during the first chemotherapy course among patients from Kaiser Permanente Southern California who received selected chemotherapy regimens without well-established FN risk...
September 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28872545/concomitant-177lu-dotatate-and-capecitabine-therapy-in-patients-with-advanced-neuroendocrine-tumors-a-long-term-outcome-toxicity-survival-and-quality-of-life-study
#12
Sanjana Ballal, Madhav P Yadav, Nishikant A Damle, Ranjit K Sahoo, Chandrasekhar Bal
PURPOSE: The purpose of this study was to evaluate the outcome, toxicity, survival, and quality of life in patients with advanced neuroendocrine tumors. METHODS: One hundred sixty-seven patients were enrolled in the study. All patients underwent baseline Ga-DOTANOC PET/CT scans. Lu-DOTATATE therapy was administered quarterly along with oral capecitabine therapy in group 1 patients (n = 88), whereas group 2 patients (n = 79) were treated only with Lu-DOTATATE. Hematologic, kidney function, liver function tests and chromogranin A levels were recorded before and after therapy at 2-week, 4-week, and 3-month intervals...
September 1, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28870517/phase-2-trial-of-capecitabine-gemcitabine-and-bevacizumab-in-sarcomatoid-renal-cell-carcinoma
#13
Abhishek Maiti, Maryam Nemati-Shafaee, Pavlos Msaouel, Lance C Pagliaro, Eric Jonasch, Nizar M Tannir, Amishi Y Shah
BACKGROUND: Patients with sarcomatoid renal-cell carcinomas (sRCC) have poor outcomes and limited treatment options. Preclinical and clinical data suggest susceptibility to cytotoxic agents and vascular endothelial growth factor-targeted therapies. We designed a phase 2 trial to evaluate the efficacy and safety of capecitabine, gemcitabine, and bevacizumab in sRCC. PATIENTS AND METHODS: Patients with metastatic or unresectable sRCC were eligible for inclusion. Patients received oral capecitabine 800 mg/m(2) twice daily on days 1 to 21 of a 28-day cycle, intravenous gemcitabine 900 mg/m(2) on days 1 and 15, and intravenous bevacizumab 10 mg/kg on days 1 and 15...
August 10, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28861862/phase-i-dose-finding-study-of-eribulin-and-capecitabine-for-metastatic-breast-cancer-jbcrg-18-cape-study
#14
Masaya Hattori, Hiroshi Ishiguro, Norikazu Masuda, Akiyo Yoshimura, Shoichiro Ohtani, Hiroyuki Yasojima, Satoshi Morita, Shinji Ohno, Hiroji Iwata
BACKGROUND: Eribulin is a nontaxane microtubule inhibitor with activity in patients with metastatic breast cancer (MBC). We conducted a phase I dose-finding study of eribulin and capecitabine in patients with MBC pretreated with anthracycline and taxane. METHODS: Women with MBC aged ≤70 years were enrolled. A 3 + 3 dose escalation design was used: level 0 dosing, eribulin (1.4 mg/m(2) intravenously on days 1 and 8) plus capecitabine [825 mg/m(2) orally twice daily (BID)]; 2-weeks-on, 1-week-off in a 21-day cycle...
August 31, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28860808/monocyte-to-lymphocyte-ratio-predicts-survival-in-patients-with-advanced-gastric-cancer-undergoing-neoadjuvant-chemotherapy
#15
Li Chen, Ying Hao, Lihua Zhu, Sen Li, Yanjiao Zuo, Yuxin Zhang, Hongjiang Song, Yingwei Xue
BACKGROUND: Currently, precise predictors in gastric cancer patients undergoing neoadjuvant chemotherapy are lacking. The study aims to investigate the prognostic value of the monocyte to lymphocyte ratio (MLR) in patients with advanced gastric cancer receiving S-1 plus oxaliplatin (SOX) or oxaliplatin and capecitabine (XELOX) neoadjuvant chemotherapy regimen. METHODS: The data from Harbin Medical University Cancer Hospital from August 2008 to September 2015 were retrospectively collected...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28860708/onychomadesis-associated-with-chemotherapy-case-report-and-mini-literature-review
#16
Ang Li, Yanqiong Li, Lingzhi Ge, Ping Li, Wenfei Li
The side effects of chemotherapy drugs have increased in recent years, and some side effects can lead to onychomadesis. A 72-year-old woman who was diagnosed with an invasive ductal carcinoma of the right breast underwent a modified radical mastectomy in April 2015, followed by chemotherapy with capecitabine and nanoparticle albumin-bound paclitaxel (nab-paclitaxel). Subsequently, the patient experienced palmoplantar redness, pain, onycholysis, a transparent serous exudate, and onychomadesis. The chemotherapy was discontinued, and the patient was treated with oral vitamin B6, a polymyxin ointment, and a high-energy red light...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28859058/preoperative-chemoradiation-with-capecitabine-irinotecan-and-cetuximab-in-rectal-cancer-significance-of-pre-treatment-and-post-resection-ras-mutations
#17
Simon Gollins, Nick West, David Sebag-Montefiore, Arthur Sun Myint, Mark Saunders, Shabbir Susnerwala, Phil Quirke, Sharadah Essapen, Leslie Samuel, Bruce Sizer, Jane Worlding, Katie Southward, Gemma Hemmings, Emma Tinkler-Hundal, Morag Taylor, Daniel Bottomley, Philip Chambers, Emma Lawrie, Andre Lopes, Sandy Beare
BACKGROUND: The influence of EGFR pathway mutations on cetuximab-containing rectal cancer preoperative chemoradiation (CRT) is uncertain. METHODS: In a prospective phase II trial (EXCITE), patients with magnetic resonance imaging (MRI)-defined non-metastatic rectal adenocarinoma threatening/involving the surgical resection plane received pelvic radiotherapy with concurrent capecitabine, irinotecan and cetuximab. Resection was recommended 8 weeks later. The primary endpoint was histopathologically clear (R0) resection margin...
August 31, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28856000/evaluation-of-the-clinical-benefits-of-adjuvant-capecitabine-monotherapy-in-elderly-women-with-breast-cancer-a-retrospective-study
#18
Yan-Shuang Li, Qing Yang, Ming Qi, Ji-Yu Li
Capecitabine is orally administered and may be safely and conveniently used in patients with cancer. The antitumor activity of capecitabine in breast cancer was mostly demonstrated in the salvage therapy setting, whereas the effect of adjuvant capecitabine monotherapy in breast cancer remains unclear. The aim of the present study was to evaluate adjuvant capecitabine monotherapy in elderly women with breast cancer. A total of 251 patients were enrolled and survival was compared between elderly breast cancer patients who received adjuvant capecitabine monotherapy and those who received no chemotherapy...
October 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28843370/a-phase-ii-study-of-preoperative-capecitabine-and-concomitant-radiation-in-women-with-advanced-breast-cancer
#19
Wendy A Woodward, Penny Fang, Lisa Arriaga, Hui Gao, Evan N Cohen, James M Reuben, Vicente Valero, Huong Le-Petross, Lavinia P Middleton, Gildy V Babiera, Eric A Strom, Welela Tereffe, Karen Hoffman, Benjamin D Smith, Thomas A Buchholz, George H Perkins
PURPOSE: To examine the response rate of gross chemo-refractory breast cancer treated with concurrent capecitabine (CAP) and radiation therapy in a prospective Phase II study. METHODS AND MATERIALS: Breast cancer patients with inoperable disease after chemotherapy, residual nodal disease after definitive surgical resection, unresectable chest wall or nodal recurrence after a prior mastectomy, or oligometastatic disease were eligible. Response by RECIST criteria was assessed after 45 Gy...
May 3, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28841916/neoadjuvant-chemotherapy-versus-surgery-first-for-resectable-pancreatic-cancer-norwegian-pancreatic-cancer-trial-1-norpact-1-study-protocol-for-a-national-multicentre-randomized-controlled-trial
#20
Knut Jørgen Labori, Kristoffer Lassen, Dag Hoem, Jon Erik Grønbech, Jon Arne Søreide, Kim Mortensen, Rune Smaaland, Halfdan Sorbye, Caroline Verbeke, Svein Dueland
BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer-related death. While surgical resection remains the foundation for potentially curative treatment, survival benefit is achieved with adjuvant oncological treatment. Thus, completion of multimodality treatment (surgical resection and (neo)adjuvant chemotherapy) to all patients and early treatment of micrometastatic disease is the ideal goal. NorPACT-1 aims to test the hypothesis that overall mortality at one year after allocation of treatment can be reduced with neoadjuvant chemotherapy in surgically treated patients with resectable pancreatic cancer...
August 25, 2017: BMC Surgery
keyword
keyword
20530
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"